Segment Information (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended September 30, 2024 and 2023 is as follows:

		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
		Three Months Ended September 30, 2024
		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
Net revenues		$	-			$	1,292			$	8,004			$	-			$	9,296
Cost of revenues (excluding amortization of acquired intangible assets)			-				238				3,645				-				3,883
Direct expenses			3,496				353				4,187				8,529				16,565
Segment contribution		$	(3,496	)		$	701			$	172			$	(8,529	)		$	(11,152	)
Indirect expenses															375		(a)		375
Loss from operations																		$	(11,527	)

(a) Components of other
Amortization															375
Total other														$	375

		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
		Three Months Ended September 30, 2023
		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
Net revenues		$	-			$	1,427			$	2,359			$	-			$	3,786
Cost of revenues (excluding amortization of acquired intangible assets)			-				398				3,204				-				3,602
Direct expenses			4,887				350				1,901				9,074				16,212
Segment contribution		$	(4,887	)		$	679			$	(2,746	)		$	(9,074	)		$	(16,028	)
Indirect expenses															83,228		(b)		83,228
Loss from operations																		$	(99,256	)

(b) Components of other
Change in fair value of contingent stock consideration															(39	)
Goodwill impairment															82,714
Amortization															553
Total other														$	83,228

Financial information by segment for the nine months ended September 30, 2024 and 2023 is as follows:

		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
		Nine Months Ended September 30, 2024
		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
Net revenues		$	-			$	3,857			$	32,231			$	-			$	36,088
Cost of revenues (excluding amortization of acquired intangible assets)			-				952				6,694				-				7,646
Direct expenses			12,383				1,216				14,385				28,159				56,143
Segment contribution		$	(12,383	)		$	1,689			$	11,152			$	(28,159	)		$	(27,701	)
Indirect expenses															1,377		(a)		1,377
Loss from operations																		$	(29,078	)

(a) Components of other
Amortization															1,377
Total other														$	1,377

		Cell Therapy				BioBanking				Degenerative Disease				Other				``Total
		Nine Months Ended September 30, 2023
		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
Net revenues		$	-			$	4,062			$	6,597			$	-			$	10,659
Cost of revenues (excluding amortization of acquired intangible assets)			-				1,355				5,052				-				6,407
Direct expenses			53,505				780				6,799				31,481				92,565
Segment contribution		$	(53,505	)		$	1,927			$	(5,254	)		$	(31,481	)		$	(88,313	)
Indirect expenses															117,289		(b)		117,289
Loss from operations																		$	(205,602	)

(b) Components of other
Change in fair value of contingent consideration liability															(104,339	)
Change in fair value of contingent stock consideration															(159	)
Goodwill impairment															112,347
IPR&D impairment															107,800
Amortization															1,640
Total other														$	117,289

Financial information by segment is as follows:

		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
		Year Ended December 31, 2023
		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
Net revenues		$	—			$	5,441			$	17,330			$	—			$	22,771
Gross profit			—				3,791				2,964				—				6,755
Direct expenses			28,694				1,752				9,720				40,876				81,041
Segment contribution			(28,694	)			2,039				(6,756	)			(40,876	)			(74,286	)
Indirect expenses															118,001		(a)		118,001
Loss from operations																		$	(192,287	)
(a) Components of other
Change in fair value of contingent consideration liability															(104,339	)
Goodwill impairment															112,347
IPR&D impairment															107,800
Amortization															2,193
Total other														$	118,001

		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
		Year Ended December 31, 2022
		Cell Therapy				BioBanking				Degenerative Disease				Other				Total
Net revenues		$	—			$	5,512			$	12,463			$	—			$	17,975
Gross profit			—				1,976				(3,666	)			—				(1,690	)
Direct expenses			75,379				1,699				10,859				56,261				144,198
Segment contribution			(75,379	)			277				(14,525	)			(56,261	)			(145,888	)
Indirect expenses															(120,288	)	(b)		(120,288	)
Loss from operations																		$	(25,600	)
(b) Components of other
Change in fair value of contingent consideration liability															(126,277	)
Change in fair value of contingent stock consideration															186
Goodwill impairment															3,610
Amortization															2,193
Total other														$	(120,288	)